#United States #New York #Investor Rights #Bronstein Gewirtz #Capricor Therapeutics

Overview of the Capricor Therapeutics Class Action

In a significant development for investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR), Bronstein, Gewirtz & Grossman LLC, a prominent law firm specializing in investor rights, has announced the filing of a class action lawsuit. This legal action targets the company and specific executives, alleging violations of federal securities laws during a critical period for the stock. The complaint has been initiated to seek compensatory damages for all individuals and entities that purchased or otherwise acquired Capricor securities from December 17, 2025, to July 26, 2026, inclusive.

Key Allegations

The allegations outlined in the class action complaint are serious and multi-faceted. During the class period, the firm claims that Capricor and its officers made several materially false and misleading statements. Notably, the lawsuit centers around the following key points:

• - Statistical Analysis Plan Changes: It is alleged that Capricor made unauthorized modifications to their pre-specified statistical analysis plan, which was used to evaluate clinical data related to the company’s product, Deramiocel. The complaint asserts that these changes were not sanctioned by the FDA before the company submitted its Biologics License Application (BLA).
• - Risk of FDA Rejection: As a result of the aforementioned changes, there is a significant claim that the FDA could deem the clinical results of Deramiocel as insufficient for demonstrating its effectiveness, potentially leading to rejection of the BLA for treating Duchenne muscular dystrophy.
• - Misleading Statements: The defendants are accused of making excessively positive statements regarding the company’s operations, business, and future prospects without a reasonable basis, thus misleading investors.

Call to Action for Investors

Members of the public who believe they have been impacted by these developments are strongly encouraged to join the class action. Interested investors can find more information and details about how to participate by visiting Bronstein, Gewirtz & Grossman’s dedicated page on this case at bgandg.com/CAPR. Those who have experienced financial losses related to their investment in Capricor have a deadline of September 28, 2026, to petition the court for a chance to be named the lead plaintiff. It is also important to note that participation in the class does not require one to be appointed as the lead plaintiff to benefit from any potential recovery.

No Upfront Costs

Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis. This means that they will cover initial costs and only seek reimbursement for expenses and legal fees from any recovery won, tacking a percentage of the total recovered amount. This system ensures that the representation is financially accessible to all investors.

Why Choose Bronstein, Gewirtz & Grossman LLC?

As a nationally recognized law firm specializing in securities fraud class actions and shareholder derivative lawsuits, Bronstein, Gewirtz & Grossman has a strong track record. The firm has managed to recover hundreds of millions of dollars for investors, reflecting their commitment to restoring investor capital and enforcing corporate accountability. The firm's founding partner, Peretz Bronstein, stated, "Our practice is centered around restoring investor capital and ensuring corporate accountability, thus upholding the integral value of the marketplace."

Conclusion

With this class action, investors in Capricor Therapeutics have an opportunity to seek justice for potential losses incurred due to misleading information from the company's executives. The developments in this lawsuit will be closely watched by market analysts and investors alike, looking to ensure accountability in the financial markets.

For ongoing updates regarding this case, interested parties are encouraged to follow Bronstein, Gewirtz & Grossman on platforms like LinkedIn, X, Facebook, and Instagram.

For additional inquiries, contact Peretz Bronstein or Nathan Miller at 917-590-0911.